Nabi readies study for NicVAX

Nabi Biopharmaceuticals of Rockville, MD says that it is ready to launch a Phase II proof-of-concept study for NicVAX, designed to help smokers give up the habit and stay off nicotine. The study is also designed to give researchers a better understanding of the optimal dose for the Phase III trial.

- read this release for more information

ALSO: Nabi announced that its senior vice president for global sales and marketing, H. LeRoux Jooste, has been terminated effective Feb. 28. Report

Suggested Articles

Passage Bio filed to raise $125 million in its IPO. Now, it has outraised that goal by $91 million with a $216 million Wall Street debut.

The ruling reflects the judge’s belief that the FDA’s interpretation of the law on clinical trial reporting “is unlawful and must be set aside.”

Trutino will apply a platform designed to yield safer, more effective cytokines to the discovery of three oncology drugs for Boehringer.